Cargando…
Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
PURPOSE: Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine diphosphate platelet receptor. CYP2C19 polymorphism has been reported to correlate with reduced antiplatelet activity of...
Autores principales: | Lee, Jun-Beom, Lee, Kyung-A, Lee, Kyung-Yul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159941/ https://www.ncbi.nlm.nih.gov/pubmed/21786436 http://dx.doi.org/10.3349/ymj.2011.52.5.734 |
Ejemplares similares
-
Effects of Triflusal and Clopidogrel on the Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping
por: Han, Sang Won, et al.
Publicado: (2017) -
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study
por: Song, Tae-Jin, et al.
Publicado: (2020) -
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
por: Kreutz, Rolf P, et al.
Publicado: (2012) -
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response
por: Kreutz, Rolf P, et al.
Publicado: (2013) -
Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis
por: Huang, Bo, et al.
Publicado: (2017)